Recent Updates
Recently added Catalysts

Tri-lipid skin barrier

Phase 2

Eczema, Infantile | Small molecule | Immunology |Harvard Bioscience, Inc.|Last Updated: Feb 27, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment398
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03742414Seal, Stopping Eczema and Allergy StudyPHASE2 ACTIVE NOT_RECRUITING 398Jun 30, 2021Jun 30, 2028Feb 27, 20265 United States, United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
number of foods each participant is sensitized to
2 years

Sensitization is defined as food-specific IgE \> 0.1 kU/L

Secondary Endpoints
The per-subject cumulative number of proven Food Allergy
2 years
Number of foods each participant is sensitized to
24 months of age
Presence, duration, and severity of dry skin and/or AD by clinical assessment
Baseline, 12, and 24 months of age and as necessary
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Control arm (Standard of care)ACTIVE_COMPARATORThe study doctors will provide standard of care with routine reactive topical products for atopic dermatitis flares
Active Intervention arm (proactive treatment)- EpiceramEXPERIMENTALParticipants will receive proactive sequential skin care with the twice-daily use of a tri-lipid skin barrier cream (SBC). Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream and/or hydrocortisone).
Interventions
NameTypeDescription
Tri-lipid skin barrier cream (Epiceram)COMBINATION_PRODUCTThe aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Fluticasone propionate Cream 0.05%COMBINATION_PRODUCTProactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Standard of CareOTHERParticipants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
Unlock Study Design Details
Eligibility Criteria
Age Range1 Week — 12 Weeks
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: 1. Participants who develop early onset visible dry skin or atopic dermatitis up to and equal to 12 weeks of age. 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. In good general health as evidenced by medical history 4....

Countries:United StatesUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT03742414studyFirstPostDate: changed